Greenwich Lifesciences Inc (GLSI)

$11.67 -0.43 (-3.55%)
Market Cap 161.75M
Revenue (ttm) 0.00
Net Income (ttm) -15.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 81,000
Avg Vol 55,372
Day's Range N/A - N/A
Shares Out 13.37M
Stochastic %K 61%
Beta 1.65
Analysts Strong Sell
Price Target $39.00

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was inco...

Industry: Biotechnology
Sector: Healthcare
Phone: 832-819-3232
Address:
Building 14, 3992 Bluebonnet Dr., Stafford, United States
mshah1615
mshah1615 Aug. 8 at 10:55 AM
$GLSI
1 · Reply
msgbrdinfo
msgbrdinfo Aug. 7 at 7:33 PM
$GLSI Traders. Short, cover, buy, sell, Short...Rinse and repeat. 🤑
1 · Reply
LIGator
LIGator Aug. 7 at 3:28 PM
$GLSI I guess I should thank the shorts. I got my monthly payment on 2 of my accounts with fully paid lending and it was the highest amount ever. Cost of borrowing was up and the share price was up. I will use the proceeds to buy more shares.
0 · Reply
doc123266
doc123266 Aug. 7 at 1:56 PM
$GLSI strong early volume.
0 · Reply
tedevan
tedevan Aug. 7 at 12:40 PM
$GLSI
0 · Reply
Waterwing
Waterwing Aug. 7 at 1:05 AM
$GLSI
0 · Reply
white__valkyrie
white__valkyrie Aug. 6 at 11:54 PM
$GLSI i am telling you bro….this not a 5billion market cap company, thanks for that @2dStar this is something more, a 98% effectiveness can be seen as a cure guys. the word “explode” does not mean that we will hit 160$ ATH, it means explode.
1 · Reply
2dStar
2dStar Aug. 6 at 9:55 PM
$GLSI
1 · Reply
2dStar
2dStar Aug. 6 at 9:53 PM
$GLSI
0 · Reply
2dStar
2dStar Aug. 6 at 9:50 PM
$GLSI
0 · Reply
Latest News on GLSI
Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 3, 2025, 8:00 AM EDT - 4 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Apr 2, 2025, 6:00 AM EDT - 4 months ago

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Mar 27, 2025, 6:00 AM EDT - 4 months ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Mar 17, 2025, 6:45 AM EDT - 5 months ago

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Feb 10, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Jan 29, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Jan 27, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Jan 23, 2025, 6:00 AM EST - 7 months ago

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Jan 22, 2025, 6:00 AM EST - 7 months ago

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Jan 17, 2025, 8:20 AM EST - 7 months ago

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Jan 14, 2025, 6:15 AM EST - 7 months ago

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Greenwich LifeSciences Partners with GIM in Italy

Nov 26, 2024, 6:00 AM EST - 9 months ago

Greenwich LifeSciences Partners with GIM in Italy

Greenwich LifeSciences Provides Update on Corporate Events

Nov 18, 2024, 6:00 AM EST - 9 months ago

Greenwich LifeSciences Provides Update on Corporate Events

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Jun 26, 2024, 2:05 PM EDT - 1 year ago

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 26, 2024, 7:33 AM EDT - 1 year ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Greenwich LifeSciences Announces $2.5 Million Private Placement

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces $2.5 Million Private Placement

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Mar 13, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Mar 12, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Feb 27, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Feb 22, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Feb 14, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Nov 21, 2023, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Greenwich LifeSciences Provides Year End Update

Dec 29, 2022, 6:48 AM EST - 2 years ago

Greenwich LifeSciences Provides Year End Update

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Dec 1, 2022, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Greenwich LifeSciences: Persevering CEO And Interesting Data

Sep 6, 2022, 5:40 PM EDT - 3 years ago

Greenwich LifeSciences: Persevering CEO And Interesting Data

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Aug 11, 2022, 10:30 AM EDT - 3 years ago

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Aug 3, 2022, 8:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Jul 28, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Jul 12, 2022, 1:18 PM EDT - 3 years ago

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Jul 12, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Jul 11, 2022, 4:15 PM EDT - 3 years ago

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Greenwich LifeSciences to Resume Stock Repurchase Program

May 23, 2022, 7:00 AM EDT - 3 years ago

Greenwich LifeSciences to Resume Stock Repurchase Program

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

May 23, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Greenwich LifeSciences: A First Look

May 19, 2022, 11:12 AM EDT - 3 years ago

Greenwich LifeSciences: A First Look

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Apr 21, 2022, 8:55 AM EDT - 3 years ago

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Apr 20, 2022, 6:10 AM EDT - 3 years ago

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Apr 19, 2022, 6:21 AM EDT - 3 years ago

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Mar 3, 2022, 9:19 AM EST - 3 years ago

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Feb 3, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Feb 1, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

Jan 24, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

Dec 15, 2021, 6:00 AM EST - 3 years ago

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings

Dec 9, 2021, 1:19 PM EST - 3 years ago

Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

Dec 9, 2021, 6:29 AM EST - 3 years ago

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

Dec 8, 2021, 7:00 AM EST - 3 years ago

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

Dec 7, 2021, 6:34 AM EST - 3 years ago

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

Dec 6, 2021, 7:15 AM EST - 3 years ago

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

Nov 18, 2021, 6:00 AM EST - 4 years ago

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference

Nov 17, 2021, 6:00 AM EST - 4 years ago

Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference

mshah1615
mshah1615 Aug. 8 at 10:55 AM
$GLSI
1 · Reply
msgbrdinfo
msgbrdinfo Aug. 7 at 7:33 PM
$GLSI Traders. Short, cover, buy, sell, Short...Rinse and repeat. 🤑
1 · Reply
LIGator
LIGator Aug. 7 at 3:28 PM
$GLSI I guess I should thank the shorts. I got my monthly payment on 2 of my accounts with fully paid lending and it was the highest amount ever. Cost of borrowing was up and the share price was up. I will use the proceeds to buy more shares.
0 · Reply
doc123266
doc123266 Aug. 7 at 1:56 PM
$GLSI strong early volume.
0 · Reply
tedevan
tedevan Aug. 7 at 12:40 PM
$GLSI
0 · Reply
Waterwing
Waterwing Aug. 7 at 1:05 AM
$GLSI
0 · Reply
white__valkyrie
white__valkyrie Aug. 6 at 11:54 PM
$GLSI i am telling you bro….this not a 5billion market cap company, thanks for that @2dStar this is something more, a 98% effectiveness can be seen as a cure guys. the word “explode” does not mean that we will hit 160$ ATH, it means explode.
1 · Reply
2dStar
2dStar Aug. 6 at 9:55 PM
$GLSI
1 · Reply
2dStar
2dStar Aug. 6 at 9:53 PM
$GLSI
0 · Reply
2dStar
2dStar Aug. 6 at 9:50 PM
$GLSI
0 · Reply
2dStar
2dStar Aug. 6 at 9:47 PM
$GLSI
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Aug. 6 at 9:24 PM
$GLSI Don’t forget that Preliminary data from April 2025 confirmed GLSI-100 elicited a potent immune response in both HLA-A02 and non-HLA-A02 patients, supporting the expansion of the non-HLA-A*02 arm to 250 patients. That was HUGE! This means it’s working.
0 · Reply
2dStar
2dStar Aug. 6 at 8:11 PM
$GLSI It would not allow me to post a link to a recent article (7/26/2025) by Diego Hoyos stating that investors on Wall Street are flocking to GLSI as hopes rise around Flamingo-01.
1 · Reply
2dStar
2dStar Aug. 6 at 8:04 PM
$GLSI Is Stocktwits shorting GLSI?
0 · Reply
OsmanGazi
OsmanGazi Aug. 6 at 7:44 PM
$GLSI all day stock available to short on charyexchange is at 10'000 , the lowest i have seen forever
0 · Reply
2dStar
2dStar Aug. 6 at 7:11 PM
$GLSI Why Stocktwits does not allow me to post news about GLSI?
0 · Reply
Gulfoil
Gulfoil Aug. 6 at 6:30 PM
$GLSI will GLSI pull another GLSI….funny how people still reference that run in 2020 when talking about other stocks. If you want another glsi run 5 x years later you dont have to look that far.
1 · Reply
doc123266
doc123266 Aug. 6 at 4:29 PM
$GLSI blocked
1 · Reply
rangervs
rangervs Aug. 6 at 4:15 PM
$LHAI pull a $GLSI !
1 · Reply
white__valkyrie
white__valkyrie Aug. 6 at 4:47 AM
$GLSI institutions dont care now about glsi, why would they? they are trading billions in the bond market, they dont care about some micro cap biotech jajaajaj and its normal. trust me, they dont care now, but the time will come.
1 · Reply
white__valkyrie
white__valkyrie Aug. 5 at 9:43 PM
$GLSI i think we are not really aware of the potencial of this company and its share price…. this can be something beyond anyone has seen
1 · Reply
doc123266
doc123266 Aug. 5 at 8:57 PM
$GLSI @2dStar absolutely love this post. The language they’re using couldn’t be more positive.
0 · Reply